Saturday 17 October 2026
Export EXOZ’s income statement to Excel — free account
eXoZymes Inc.
EXOZ Healthcare Biotechnology
eXoZymes Inc.’s revenue for fiscal 2023 (year ended December 2023) was $70,100.00. In the quarter to June 2026, EPS fell 17.9%, free cash flow fell 3.25% and total debt fell 52.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.09
0.09
+2.25%
Follow EXOZ
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
0.00 | — | — |
P/S ratio |
0.00 | — | — |
Altman Z″-Score (non-manufacturers) |
(11.28) | — | — |
P/FCF ratio |
0.00 | — | — |
P/Operating CF |
(99.87) | — | — |
P/B ratio |
0.00 | — | — |
Price to Tangible BV |
0.00 | — | — |
EV/Sales |
0.00 | — | — |
EV/EBITDA |
0.00 | — | — |
EV/Operating CF |
(15.99) | — | — |
EV/FCF |
(14.77) | — | — |
Quick Ratio |
0.39 | 7.84 | 2.27 |
Current Ratio |
0.50 | 8.12 | 2.51 |
Net Debt/EBITDA |
0.04 | 1.70 | 0.31 |
Debt/Assets |
0.00% | 0.00% | 1.08% |
Debt/Equity |
0.00 | 0.00 | 0.02 |
Asset Turnover |
0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.58 | 1.45 | 0.71 |
Capex/Depreciation |
(1.99) | (1.86) | (0.72) |
| 0.00% | (116.80%) | (132.56%) | |
| 0.00% | (70.65%) | (96.38%) | |
ROIC |
0.00% | (528.52%) | (1,438.03%) |
Return on Tangible Assets |
454.70% | (56.52%) | (291.95%) |
Average Days of Receivables |
4,594.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
752.50% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
1,909.84% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
401.57% | 0.00% | 0.00% |
Graham Net Nets |
(0.11) | — | — |
Graham Number |
0.00 | — | — |
Earnings Yield |
(8.41%) | — | — |
Free Cash Flow Yield |
(7.17%) | — | — |
Revenue per Share |
0.01 | 0.00 | 0.00 |
Operating CF per Share |
(0.19) | (1.30) | (0.78) |
Capex per Share |
(0.05) | (0.06) | (0.02) |
Free Cash Flow per Share |
(0.24) | (1.36) | (0.80) |
Cash per Share |
0.01 | 1.48 | 0.36 |
Shareholders Equity per Share |
(0.06) | 1.59 | 0.41 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(0.06) | 1.59 | 0.41 |
Free Cash Flow |
(1.47) | (8.90) | (6.67) |
Working Capital |
(1.20) | 9.49 | 2.37 |
Capital Expenditures |
(0.29) | (0.40) | (0.17) |
Net Current Asset Value |
(2.73) | 8.21 | 1.37 |
EV/EBIT |
0.00 | — | — |
Capex to Sales |
4.12 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | — | — |
| Other line items | |||
Depreciation/Fixed assets |
0.19 | 0.24 | 0.31 |
Cash ROIC |
462.43% | (44.20%) | (102.63%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.81 | 0.63 |
Average Payables |
— | 0.81 | 1.08 |
Average Assets |
— | 8.30 | 9.50 |
Average Common Equity |
— | 5.02 | 6.91 |
Columns are period end dates